NO20070089L - DPP-IV inhibitorer - Google Patents
DPP-IV inhibitorerInfo
- Publication number
- NO20070089L NO20070089L NO20070089A NO20070089A NO20070089L NO 20070089 L NO20070089 L NO 20070089L NO 20070089 A NO20070089 A NO 20070089A NO 20070089 A NO20070089 A NO 20070089A NO 20070089 L NO20070089 L NO 20070089L
- Authority
- NO
- Norway
- Prior art keywords
- dpp
- inhibitors
- compounds
- relates
- medicament
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
Oppfinnelsen angår forbindelser med formel (I) hvor Z, R1'3 og A har betydningene angitt i beskrivelsen og kravene. Nevnte forbindelser er anvendelige som DPP-IV-inhibitorer. Oppfinnelsen angår også fremstilling av slike forbindelser så vel som produksjon og anvendelse derav som medikament.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04013511A EP1604980A1 (en) | 2004-06-08 | 2004-06-08 | DPP-IV inhibitors |
PCT/EP2005/006161 WO2005121089A1 (en) | 2004-06-08 | 2005-06-08 | Dpp-iv inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20070089L true NO20070089L (no) | 2007-01-05 |
Family
ID=34925295
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20070089A NO20070089L (no) | 2004-06-08 | 2007-01-05 | DPP-IV inhibitorer |
Country Status (14)
Country | Link |
---|---|
US (1) | US20070265261A1 (no) |
EP (2) | EP1604980A1 (no) |
JP (1) | JP2008501751A (no) |
KR (1) | KR20070026788A (no) |
CN (1) | CN101001838A (no) |
AU (1) | AU2005251910A1 (no) |
BR (1) | BRPI0510849A (no) |
CA (1) | CA2569535A1 (no) |
IL (1) | IL179305A0 (no) |
MX (1) | MXPA06014324A (no) |
NO (1) | NO20070089L (no) |
RU (1) | RU2006140796A (no) |
WO (1) | WO2005121089A1 (no) |
ZA (1) | ZA200609730B (no) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
TW200806627A (en) * | 2006-04-11 | 2008-02-01 | Novartis Ag | Organic compounds |
KR20090004950A (ko) | 2006-04-12 | 2009-01-12 | 프로비오드룩 아게 | 효소 억제제 |
WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
WO2008065141A1 (en) | 2006-11-30 | 2008-06-05 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
BRPI0718874A2 (pt) * | 2006-12-22 | 2015-06-23 | Novartis Ag | Compostos orgânicos |
JP5667440B2 (ja) | 2007-04-18 | 2015-02-12 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体 |
WO2009003681A1 (en) * | 2007-07-02 | 2009-01-08 | Santhera Pharmaceuticals (Schweiz) Ag | Dpp-iv inhibitors |
EP2019099A1 (en) * | 2007-07-02 | 2009-01-28 | Santhera Pharmaceuticals (Schweiz) AG | Dpp-IV inhibitors |
EP2146210A1 (en) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
CN108635350A (zh) * | 2009-01-12 | 2018-10-12 | 爱尔皮奥治疗有限公司 | 治疗血管渗漏综合征的方法 |
MX2012002993A (es) | 2009-09-11 | 2012-04-19 | Probiodrug Ag | Derivados heterociclicos como inhibidores de ciclasa glutaminilo. |
JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
MX2012010470A (es) | 2010-03-10 | 2012-10-09 | Probiodrug Ag | Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5). |
US8541596B2 (en) | 2010-04-21 | 2013-09-24 | Probiodrug Ag | Inhibitors |
WO2012123563A1 (en) | 2011-03-16 | 2012-09-20 | Probiodrug Ag | Benz imidazole derivatives as inhibitors of glutaminyl cyclase |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
EP2540649B1 (en) | 2011-06-27 | 2013-12-11 | Metso Paper Inc. | Method and arrangement in connection with an unwinder |
EP3461819B1 (en) | 2017-09-29 | 2020-05-27 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE122010000020I1 (de) * | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
TW492957B (en) * | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
WO2003000180A2 (en) * | 2001-06-20 | 2003-01-03 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
ATE318139T1 (de) * | 2001-06-20 | 2006-03-15 | Merck & Co Inc | Dipeptidylpeptidase-hemmer zur behandlung von diabetes |
EP1461339B1 (en) * | 2001-12-28 | 2010-04-28 | Acadia Pharmaceuticals Inc. | Spiroazacyclic compounds as monoamine receptor modulators |
AU2003238046A1 (en) * | 2002-06-27 | 2004-01-19 | Actelion Pharmaceuticals Ltd | Substituted 3- and 4- aminomethylpiperidines for use as beta-secretase in the treatment of alzheimer's disease |
AU2003251869A1 (en) * | 2002-07-15 | 2004-02-02 | Merck & Co., Inc. | Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes |
-
2004
- 2004-06-08 EP EP04013511A patent/EP1604980A1/en not_active Withdrawn
-
2005
- 2005-06-08 US US11/569,552 patent/US20070265261A1/en not_active Abandoned
- 2005-06-08 AU AU2005251910A patent/AU2005251910A1/en not_active Abandoned
- 2005-06-08 EP EP05750581A patent/EP1791817A1/en not_active Withdrawn
- 2005-06-08 CN CNA2005800188185A patent/CN101001838A/zh active Pending
- 2005-06-08 JP JP2007526293A patent/JP2008501751A/ja not_active Withdrawn
- 2005-06-08 RU RU2006140796/04A patent/RU2006140796A/ru not_active Application Discontinuation
- 2005-06-08 MX MXPA06014324A patent/MXPA06014324A/es unknown
- 2005-06-08 CA CA002569535A patent/CA2569535A1/en not_active Abandoned
- 2005-06-08 KR KR1020077000367A patent/KR20070026788A/ko active IP Right Grant
- 2005-06-08 BR BRPI0510849-7A patent/BRPI0510849A/pt not_active IP Right Cessation
- 2005-06-08 WO PCT/EP2005/006161 patent/WO2005121089A1/en active Application Filing
-
2006
- 2006-11-15 IL IL179305A patent/IL179305A0/en unknown
- 2006-11-22 ZA ZA200609730A patent/ZA200609730B/en unknown
-
2007
- 2007-01-05 NO NO20070089A patent/NO20070089L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
ZA200609730B (en) | 2008-01-30 |
JP2008501751A (ja) | 2008-01-24 |
RU2006140796A (ru) | 2008-07-20 |
KR20070026788A (ko) | 2007-03-08 |
CA2569535A1 (en) | 2005-12-22 |
BRPI0510849A (pt) | 2007-11-27 |
IL179305A0 (en) | 2007-03-08 |
US20070265261A1 (en) | 2007-11-15 |
MXPA06014324A (es) | 2007-05-04 |
WO2005121089A1 (en) | 2005-12-22 |
CN101001838A (zh) | 2007-07-18 |
EP1604980A1 (en) | 2005-12-14 |
AU2005251910A1 (en) | 2005-12-22 |
EP1604980A8 (en) | 2006-03-15 |
EP1791817A1 (en) | 2007-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20070089L (no) | DPP-IV inhibitorer | |
NO20065946L (no) | DPP-IV-inhibitorer | |
NO20064032L (no) | DPP-IV inhibitorer | |
NO20062644L (no) | DPP-IV inhibitorer | |
TNSN06409A1 (en) | Novel fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof | |
MX2007000505A (es) | Derivados de oxindol sustituidos y medicamentos que contienen los mismos. | |
TW200602338A (en) | Selected CGRP antagonists, process for preparing them and their use as pharmaceutical compositions | |
UA102534C2 (en) | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]-dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid | |
WO2007015017A3 (fr) | Nouveaux derives de polyquinoleines et leur utilisation therapeutique | |
NO20071617L (no) | Indozolonderivater som 11B-HSD1-inhibitorer | |
TW200640859A (en) | Substituted bis aryl and heteroaryl compounds as selective 5HT2A antagonists | |
NO20093200L (no) | Tiazolidinderivater | |
NO20070445L (no) | Pyrimidinderivater. | |
NO20070224L (no) | 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav | |
ATE493386T1 (de) | Trans-3-aza-bicyclo-ä3.1.0ü-hexan-derivate | |
NO20076648L (no) | Novel thiophene derivatives | |
TW200606151A (en) | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | |
NO20062021L (no) | Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika | |
GEP20115166B (en) | 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS | |
IL176914A0 (en) | Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, method for the production thereof and their use as medicaments | |
BRPI0519267A2 (pt) | derivado de quinolina, seu uso, produÇço e medicamento contendo o mesmo | |
TW200621703A (en) | Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | |
GB0602951D0 (en) | Organic Compounds | |
WO2008023003A8 (de) | Arzneimittelkombinationen zur behandlung von atemwegserkrankungen | |
TNSN06233A1 (en) | 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, methods for production and use thereof as medicaments |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |